Literature DB >> 1950706

Directed plasminogen activation at the surface of normal and malignant cells.

J Pöllänen1, R W Stephens, A Vaheri.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1950706     DOI： 10.1016/s0065-230x(08)61002-7

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  38 in total

1.  Cell surface antigens of Mycoplasma species bovine group 7 bind to and activate plasminogen.

Authors:  Kylie Bower; Steven P Djordjevic; Nicholas M Andronicos; Marie Ranson
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

2.  High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma.

Authors:  Jun Du; Jian-Hua Zheng; Xu-Sheng Chen; Qing Yang; Yan-Hui Zhang; Lei Zhou; Xin Yao
Journal:  Int J Clin Oncol       Date:  2012-05-19       Impact factor: 3.402

3.  Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

Authors:  R W Colman; R A Pixley; S Najamunnisa; W Yan; J Wang; A Mazar; K R McCrae
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.

Authors:  Z L Gokaslan; S K Chintala; J E York; V Boyapati; S Jasti; R Sawaya; G Fuller; D M Wildrick; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

5.  Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.

Authors:  Y Go; S K Chintala; S Mohanam; Z Gokaslan; B Venkaiah; R Bjerkvig; K Oka; G L Nicolson; R Sawaya; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

6.  Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.

Authors:  B Lyons-Giordano; D Loskutoff; C S Chen; G Lazarus; M Keeton; P J Jensen
Journal:  Histochemistry       Date:  1994-02

7.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

8.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

9.  Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.

Authors:  C Festuccia; V Dolo; F Guerra; S Violini; P Muzi; A Pavan; M Bologna
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

10.  PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.

Authors:  Laetitia Devy; Shafaat A Rabbani; Mark Stochl; Mary Ruskowski; Ian Mackie; Laurent Naa; Mark Toews; Reinoud van Gool; Jie Chen; Art Ley; Robert C Ladner; Daniel T Dransfield; Paula Henderikx
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.